Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the ...

Abbott Laboratories (ABT) delivered a strong Q2 2026 performance that surprised Wall Street, with the healthcare giant posting a double beat on both top and bottom lines on July 16, 2026. The earnings ...

Abbott Laboratories has had a rough year in the market, and the recent product news now puts a sharper spotlight on whether ...

Abbott Laboratories (NYSE:ABT) offers investors access to several segments of the healthcare industry, including diabetes ...

Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant ...

Abbott Laboratories is now fairly valued after a 26% decline from its 2021 highs, but I maintain a Hold rating. ABT's Q1/26 saw 7.8% revenue growth, with medical devices leading, but operating income ...

Follow Abbott Laboratories as investors assess medical devices and diagnostics, the current catalyst, execution risks and the company evidence that may shape its next market move.

Abbott Laboratories stock last stood at EUR 93.01 before weekend trading on October 16, 2026. The next Xetra session is ...